vs
Amphastar Pharmaceuticals, Inc.（AMPH）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是Amphastar Pharmaceuticals, Inc.的1.6倍（$297.2M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 4.9%，领先8.4%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -3.2%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $19.7M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 3.0%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
AMPH vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.6倍
$183.1M
营收增速更快
AMPH
高出1.3%
-3.2%
净利率更高
AMPH
高出8.4%
4.9%
自由现金流更多
AMPH
多$4.9M
$19.7M
两年增速更快
AMPH
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $297.2M |
| 净利润 | $24.4M | $14.6M |
| 毛利率 | 46.8% | 37.6% |
| 营业利润率 | 19.4% | 6.3% |
| 净利率 | 13.3% | 4.9% |
| 营收同比 | -1.8% | -3.2% |
| 净利润同比 | -35.7% | -23.9% |
| 每股收益（稀释后） | $0.51 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHSCVL
| Q4 25 | $183.1M | $297.2M | ||
| Q3 25 | $191.8M | $306.4M | ||
| Q2 25 | $174.4M | $277.7M | ||
| Q1 25 | $170.5M | $262.9M | ||
| Q4 24 | $186.5M | $306.9M | ||
| Q3 24 | $191.2M | $332.7M | ||
| Q2 24 | $182.4M | $300.4M | ||
| Q1 24 | $171.8M | $280.2M |
净利润AMPHSCVL
| Q4 25 | $24.4M | $14.6M | ||
| Q3 25 | $17.4M | $19.2M | ||
| Q2 25 | $31.0M | $9.3M | ||
| Q1 25 | $25.3M | $14.7M | ||
| Q4 24 | $38.0M | $19.2M | ||
| Q3 24 | $40.4M | $22.6M | ||
| Q2 24 | $37.9M | $17.3M | ||
| Q1 24 | $43.2M | $15.5M |
毛利率AMPHSCVL
| Q4 25 | 46.8% | 37.6% | ||
| Q3 25 | 51.4% | 38.8% | ||
| Q2 25 | 49.6% | 34.5% | ||
| Q1 25 | 50.0% | 34.9% | ||
| Q4 24 | 46.5% | 36.0% | ||
| Q3 24 | 53.3% | 36.1% | ||
| Q2 24 | 52.2% | 35.6% | ||
| Q1 24 | 52.4% | 35.6% |
营业利润率AMPHSCVL
| Q4 25 | 19.4% | 6.3% | ||
| Q3 25 | 13.2% | 8.2% | ||
| Q2 25 | 24.2% | 4.3% | ||
| Q1 25 | 21.9% | 5.3% | ||
| Q4 24 | 24.2% | 8.0% | ||
| Q3 24 | 29.8% | 9.0% | ||
| Q2 24 | 30.3% | 7.5% | ||
| Q1 24 | 27.9% | 7.1% |
净利率AMPHSCVL
| Q4 25 | 13.3% | 4.9% | ||
| Q3 25 | 9.0% | 6.3% | ||
| Q2 25 | 17.8% | 3.4% | ||
| Q1 25 | 14.8% | 5.6% | ||
| Q4 24 | 20.4% | 6.3% | ||
| Q3 24 | 21.1% | 6.8% | ||
| Q2 24 | 20.8% | 5.8% | ||
| Q1 24 | 25.1% | 5.5% |
每股收益（稀释后）AMPHSCVL
| Q4 25 | $0.51 | $0.53 | ||
| Q3 25 | $0.37 | $0.70 | ||
| Q2 25 | $0.64 | $0.34 | ||
| Q1 25 | $0.51 | $0.53 | ||
| Q4 24 | $0.74 | $0.70 | ||
| Q3 24 | $0.78 | $0.82 | ||
| Q2 24 | $0.73 | $0.63 | ||
| Q1 24 | $0.81 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $107.7M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $683.2M |
| 总资产 | $1.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHSCVL
| Q4 25 | $282.8M | $107.7M | ||
| Q3 25 | $276.2M | $91.9M | ||
| Q2 25 | $231.8M | $93.0M | ||
| Q1 25 | $236.9M | $123.1M | ||
| Q4 24 | $221.6M | $91.1M | ||
| Q3 24 | $250.5M | $84.5M | ||
| Q2 24 | $217.8M | $69.5M | ||
| Q1 24 | $289.6M | $111.2M |
总债务AMPHSCVL
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHSCVL
| Q4 25 | $788.8M | $683.2M | ||
| Q3 25 | $776.7M | $670.7M | ||
| Q2 25 | $757.5M | $653.6M | ||
| Q1 25 | $751.3M | $649.0M | ||
| Q4 24 | $732.3M | $635.7M | ||
| Q3 24 | $727.7M | $618.5M | ||
| Q2 24 | $713.3M | $597.8M | ||
| Q1 24 | $672.4M | $583.4M |
总资产AMPHSCVL
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.0B |
负债/权益比AMPHSCVL
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $33.6M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $19.7M |
| 自由现金流率自由现金流/营收 | 13.4% | 6.6% |
| 资本支出强度资本支出/营收 | 4.5% | 4.7% |
| 现金转化率经营现金流/净利润 | 1.35× | 2.30× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $35.1M |
8季度趋势，按日历期对齐
经营现金流AMPHSCVL
| Q4 25 | $32.9M | $33.6M | ||
| Q3 25 | $52.6M | $13.3M | ||
| Q2 25 | $35.6M | $-9.6M | ||
| Q1 25 | $35.1M | $44.5M | ||
| Q4 24 | $29.0M | $17.3M | ||
| Q3 24 | $60.0M | $23.7M | ||
| Q2 24 | $69.1M | $17.1M | ||
| Q1 24 | $55.3M | $53.4M |
自由现金流AMPHSCVL
| Q4 25 | $24.6M | $19.7M | ||
| Q3 25 | $47.2M | $2.2M | ||
| Q2 25 | $25.0M | $-23.0M | ||
| Q1 25 | $24.4M | $36.2M | ||
| Q4 24 | $16.6M | $8.3M | ||
| Q3 24 | $46.2M | $18.2M | ||
| Q2 24 | $63.1M | $6.9M | ||
| Q1 24 | $46.5M | $40.7M |
自由现金流率AMPHSCVL
| Q4 25 | 13.4% | 6.6% | ||
| Q3 25 | 24.6% | 0.7% | ||
| Q2 25 | 14.3% | -8.3% | ||
| Q1 25 | 14.3% | 13.8% | ||
| Q4 24 | 8.9% | 2.7% | ||
| Q3 24 | 24.1% | 5.5% | ||
| Q2 24 | 34.6% | 2.3% | ||
| Q1 24 | 27.1% | 14.5% |
资本支出强度AMPHSCVL
| Q4 25 | 4.5% | 4.7% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 4.8% | ||
| Q1 25 | 6.3% | 3.2% | ||
| Q4 24 | 6.7% | 3.0% | ||
| Q3 24 | 7.2% | 1.7% | ||
| Q2 24 | 3.3% | 3.4% | ||
| Q1 24 | 5.1% | 4.5% |
现金转化率AMPHSCVL
| Q4 25 | 1.35× | 2.30× | ||
| Q3 25 | 3.03× | 0.69× | ||
| Q2 25 | 1.15× | -1.03× | ||
| Q1 25 | 1.39× | 3.04× | ||
| Q4 24 | 0.76× | 0.90× | ||
| Q3 24 | 1.48× | 1.05× | ||
| Q2 24 | 1.82× | 0.99× | ||
| Q1 24 | 1.28× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SCVL
暂无分部数据
